Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 over exp prostate cancer sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Preclinical - Pdx & cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) inhibited growth of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture and in a patient-derived xenograft (PDX) model, but did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). 34753775
ERBB3 over exp prostate cancer predicted - sensitive HER3 (ERBB3) Antibody Patritumab Preclinical - Pdx & cell culture Actionable In a preclinical study, Patritumab (U3-1287) treatment decreased viability of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture but did not inhibit tumor growth in a patient-derived xenograft (PDX) model, and did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). 34753775
ERBB3 over exp breast cancer sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Preclinical - Cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line overexpressing Erbb3 (Her3) in culture (PMID: 35503762). 35503762
ERBB3 over exp Her2-receptor positive breast cancer predicted - sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial, Patritumab deruxtecan (U3-1402) treatment demonstrated safety and efficacy in patients with metastatic ERBB2 (HER2)-positive breast cancer expressing high levels of ERBB3 (HER3) (>/=75% membrane positivity), resulting in an objective response rate of 42.9% (6/14, all partial responses), stable disease of 50.0% (7/14), and a median duration of response of 8.3 months (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 1002; NCT02980341). detail...
ERBB3 over exp triple-receptor negative breast cancer predicted - sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial, Patritumab deruxtecan (U3-1402) treatment demonstrated safety and efficacy in patients with metatstatic triple-negative breast cancer expressing high levels of ERBB3 (HER3) (>/=75% membrane positivity), resulting in an objective response rate of 22.6% (12/53, all partial responses), stable disease of 56.6% (30/53), and a median duration of response of 5.9 months (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 1002; NCT02980341). detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting 1
NCT04965766 Phase II Patritumab deruxtecan Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST) Recruiting FRA 0